AprilBio Issures 50 Billion Won Convertible Preferred Shares for R&D, 5.22% Dilution Mitigated by Premium Pricing and Lock-Up

AprilBio is issuing 1,222,254 convertible preferred shares at 40,908 won per share to IMM Asset Management and IMM Scale-up Bio No.1 LLC, raising 50 billion won for operating funds.
The issue price is an 18.16% premium over the reference price of 34,620 won, and shares are subject to a one-year lock-up, limiting short-term dilution pressure.
The convertible preferred shares carry a 1% minimum cumulative participating dividend preference over common shares, and the conversion price is adjustable upon future issuances under similar terms.
Funds will be allocated to R&D expenses through 2028 and beyond, supporting pipeline development and potential enterprise value enhancement.
[AI Summary]AprilBio raised 50 billion won via convertible preferred shares for R&D. The 5.22% dilution is moderate but mitigated by a premium issue price and a one-year lock-up. Funds are allocated to long-term R&D, and participation by an SPC backed by the National Pension Service enhances governance credibility.